Sanuwave Health reports preliminary Q2 2024 revenue of $7.0-7.2M, highest quarterly revenue in history

SANUWAVE Health, Inc.

2024-Q2 EPS reported $0.00 revenue$12,948,000

Preliminary Q2 2024 revenue $7.0M-$7.2M; up 50%-54% vs Q2 2023 and highest quarterly revenue ever.
UltraMist revenue grew >60% YoY and represents ~97% of total company revenue.
UltraMist applicator sales set all-time quarterly record, accounting for ~65% of total revenue.
Company expects to release full Q2 results in mid-August 2024; guidance at upper end of prior range.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.